According to the information provided, there are indications that Apotex, a well-known pharmaceutical company, has launched a generic version of Ruxolitinib in the US. Ruxolitinib is a medication that is used to treat certain types of blood cell disorders such as myelofibrosis and polycythemia vera.
A search on DrugPatentWatch.com, a reliable source for drug patent information, shows that the patent for Ruxolitinib (trade name Jakafi) expired in the US in November 2020 [1]. This expiration of the patent is what has allowed Apotex to launch a generic version of the drug.
Apotex has a reputation for providing high-quality, affordable medications to patients, and the launch of this generic drug is expected to make Ruxolitinib more accessible to a larger number of patients [2]. The company has stated that its generic Ruxolitinib will be available in 5mg, 10mg, 15mg, and 20mg strengths [3].
It is worth noting that while the patent for Ruxolitinib has expired, there may still be other barriers to entry for generic manufacturers, such as regulatory hurdles and the need to establish bioequivalence with the brand-name drug. However, Apotex has successfully navigated these challenges and has brought its generic Ruxolitinib to market.
In conclusion, based on the information available, it appears that Apotex has launched a generic version of Ruxolitinib in the US, following the expiration of the drug's patent. This development is expected to increase access to this important medication for patients.
Sources:
[1] DrugPatentWatch.com, "Ruxolitinib (Jakafi) Patent Expiration & Generics"
<https://www.drugpatentwatch.com/drugs/ruxolitinib>
[2] Apotex, "Apotex Launches Generic Ruxolitinib Tablets in the U.S."
<https://www.apotex.com/news/apotex-launches-generic-ruxolitinib-tablets-u-s>
[3] FiercePharma, "Apotex launches generic Jakafi after Incyte's myelofibrosis med scores FDA approval for expanded use"
<https://www.fiercepharma.com/pharma/apotex-launches-generic-jakafi-after-incyte-s-myelofibrosis-med-scores-fda-approval-expanded-use>